6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

F-3 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

EFFECT - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

424B3 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

F-1 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

Canaccord Genuity reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $21.00 from $20.00 previously

HC Wainwright & Co. reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $29.00 previously

SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysisContinuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional PathologyTEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metab

Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects.Galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity lineTEL AVIV, Israel, Sept. 19, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for fibroinflammatory indications announced today that based on the recently published results from the Open-Label part of its Phase 3 NASH study, new scientific publications on the role of SCD1 as a cr

TEL AVIV, Israel, April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC").     The report is available on the SEC's website, at www.sec.gov and Galmed's Investor Relations website, at https://galmedpharma.investorroom.com/sec-filings. Shareholders can obtain copies of Galmed's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Galmed's Investo

TEL AVIV, Israel, March 15, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis. The patent was granted in France, Germany, Italy, the Netherlands and the United Kingdom and the approval of the patent in the United States and other countries is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until September 2039.

TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study. In May 2023, Galmed announced the pivoting of its clinical program to evaluate the safety and efficacy of its lead compound, Aramchol meglumine, for the treatment PSC. All work was designed to ensure the initiation of a proof-of-concept Phase 2a study in the last quarter of 2023. Prior to the initiation of the Ph 2a study, Galmed had planned to complete a Ph1 pharmacokin

TEL AVIV, Israel, Sept. 26, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis. A similar patent was already granted in Mexico. The approval of the patent in the US and the rest of the world is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until November 2037.     Previously, Galmed reported results showing significant anti-fibrotic effects of Aramchol in a pre-clinical model of lung

TEL AVIV, Israel, Sept. 22, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.   Further, the Rules also provide the Company a compliance period of 180 calendar days to regain compliance. According to the Letter, the Company has from

TEL AVIV, Israel, July 14, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the "Offering"). The gross proceeds of the Offering to the Company, before placement agent fees and estimated offering expenses, are expected to be approximately $7.0 mi

OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, is delighted to announce the first step in its strategic partnership with OnKai, where OnKai will apply its artificial intelligence (AI), models for enrollment and execution of clinical trials in underserved communities, starting with Galmed's innovative Primary Sclerosing Cholangitis (PSC) clinical development program. PSC is a rare, severe, chronic disease where progression is predominantly determined by biliar

TEL AVIV, Israel, June 1, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments Recent Developments Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC), a rare disease for which there is no approved treatment;Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University;Formed a str

TEL AVIV, Israel, June 1, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments Recent Developments Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC), a rare disease for which there is no approved treatment;Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University;Formed a str

TEL AVIV, Israel, Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis and other fibrotic indications, provides today a business update and reports financial results for the three and six months ended June 30, 2022. Recent Developments Discontinuing the Open Label Part of the ARMOR study having reached its objectives while refocusing research and development on advancing Aramchol for new anti-fibrotic indications.Implementing a cost reduction plan that includes reduction in headc

TEL AVIV, Israel, May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022.     Recent Developments Announced that Company's clinical development strategy will expand into new anti-fibrotic indications to maximize the potential of its lead compound, Aramchol while at the same time discontinuing the Open Label Part of the Armor Study having reached its objectives.Company evaluating its strategic alternatives and its structuring to best enhance shareholder value and achieve its goals.Fina

- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - TEL AVIV, Israel, May 2, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and twelve months ended December 31, 2021.     Recent Clinical & Scientific Developments Announced positive interim results from Open-Label part of the ARMOR study sh

TEL AVIV, Israel, April 26, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Monday, May 2, 2022, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the fourth quarter and year ended December 31, 2021.      Conference Call & Webcast: Monday May 2, 2022, 8:30 AM ETToll Free:    

TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and nine months ended September 30, 2021. Recent Clinical & Scientific Developments Announced positive results of the

-- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at AASLD Late Breaker Presentations -- -- Statistically significant reductions in biomarkers associated with liver fibrosis including ALT, AST, Fib-4 and ProC-3 was also observed in ~ 50 patients -- -- Results are an early indication that higher dose of Aramchol could provide statistically and clinically meaningful effect on fibrosis in the double-blind placebo controlled regulatory part for submission of an NDA under Sub-part H-- Galmed's management team will host a conference call and webcast to provide an update on current developments w

TEL AVIV, Israel, Nov. 1, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled post-baseline biopsy.  End of treatment biopsies were performed for 8 patients at 24 weeks, 6 at 48 weeks and 2 at 72 weeks. Altogether treatment with Aramchol reduced fibrosis progression in 15 out of the 16 patients. 8 out of the 16 patients (50%) showed fibrosis improvement by ≥1 stage (4 of 8 after 24 weeks, 3 of 6 after 48 weeks and 1 of 2 after 72 weeks). I

TEL AVIV, Israel, Aug. 5, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and six months ended June 30, 2021. The Company will host a conference call and webcast at 08:30 ET today. Recent Clinical & Scientific Developments The FDA agreed with Galmed's plan to use Aramchol meglumine in the randomized double-

Shares of Mainz Biomed N.V. (NASDAQ:MYNZ) rose sharply in today's pre-market trading after the company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test. Mainz Biomed shares jumped 16% to $0.5534 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Pineapple Energy Inc. (NASDAQ:PEGY) rose 85% to $2.22 in pre-market trading. Pineapple Energy engaged Conduit Capital to provide structural internal support, staffing, and assistance with capital raising activities. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) shares rose 43.5% to $13.26 in pre-market trading after gaining 127% on Mon

Shares of KKR & Co. Inc. (NYSE:KKR) rose sharply in today's pre-market trading after it was announced the company will join the S&P 500. S&P Dow Jones Indices announced late Friday changes to various S&P indices, coinciding with the quarterly rebalance. KKR will take the place of Comerica Inc. (NYSE:CMA) in the broader gauge. KKR & Co. shares jumped 10.4% to $108.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) rose 165% to $5.05 in today's pre-market trading. New Horizon Aircraft Ltd. (NASDAQ:HOVR) gained 90.1% to $1.37 in pre-market trading after declining around 8% on Frid

Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart’s quarterly sales came in at $1.29 billion versus expectations of $1.28 billion, according to data from Benzinga Pro. PriceSmart shares surged 4.6% to $86.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Marin Software Incorporated (NASDAQ:MRIN) shares rose 76.1% to $0.5054 in pre-market trading after the company announced upgrades to its Microsoft Corp (NASDAQ:MSFT) adver

Shares of Agenus Inc. (NASDAQ:AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ:AGEN) declined 17% to $0.4181 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Auddia Inc. (NASDAQ:AUUD) shares jumped 231.7% to $4.72 after the company announced the USPTO awarded it with U.S. Patent 11,935,520 for the core AI technology the company uses in its flagship faidr app to deliver ad-free AM/FM radio stations to paid subscribers. Longeveron Inc. (NASDAQ:LGVN) shares climbed 93.2% to $4.2499 after the company submitted paperwork for a share offering. UTime Limited (NASDAQ:WTO) gained

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations. Esperion Therapeutics shares climbed 7.1% to $3.47 pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Longeveron Inc. (NASDAQ:LGVN) rose 93.2% to $4.25 in pre-market trading after gaining 8% on Friday. Antelope Enterprise Holdings Limited (NASDAQ:AEHL) shares rose 47% to $2.20 in pre-market trading after declining 5% on Friday. On April 1, Antelope Enterprise announced preliminary full year 2023 revenue of $70.4 mil

- SEC Filing

U.S. stocks traded lower toward the end of trading on Tuesday following the release of FOMC minutes. The Dow traded down 0.17% to 35,092.02 while the NASDAQ fell 0.59% to 14,200.33. The S&P 500 also fell, dropping, 0.17% to 4,539.87. Check This Out: CrowdStrike To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Tuesday   Leading and Lagging Sectors   Health care shares surged by 0.8% on Tuesday. In trading on Tuesday, information technology shares fell by 0.9%.   Top Headline   Sales of previously owned homes in the U.S. fell 4.1% month-over-month to an annualized rate of 3.79 million units in October.   Equities Trading UP   Burlington Stores, Inc. (NYSE:BURL) shares

Shares of American Eagle Outfitters, Inc. (NYSE:AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the consensus of $1.28 billion. EPS of $0.49 surpassed the consensus of $0.48. For FY23, AEO revised guidance for revenue to be up mid-single digits Y/Y from growth in low single digits Y/Y earlier. American Eagle fell 16.4% to $16.52 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Safe and Green Development Corporation (NASDAQ:SGD) shares gained 66% to $4.7119. Safe and Green Development unveiled a Letter of Intent for integration of real estate AI softwar

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday. The Dow traded down 0.25% to 35,062.35 while the NASDAQ fell 0.81% to 14,168.79. The S&P 500 also fell, dropping, 0.34% to 4,531.77. Check This Out: CrowdStrike To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Tuesday   Leading and Lagging Sectors   Materials shares surged by 0.6% on Tuesday. In trading on Tuesday, information technology shares fell by 1.1%.   Top Headline   Shares of Burlington Stores, Inc. (NYSE:BURL) jumped more than 20% on Tuesday after the company reported third-quarter financial results and issued guidance. Burlington posted adjust